NasdaqCM - Nasdaq Real Time Price USD

KALA BIO, Inc. (KALA)

6.57

-0.12

(-1.79%)

At close: June 7 at 4:00 PM EDT

6.79

+0.22

(+3.35%)

After hours: June 7 at 6:01 PM EDT

KALA BIO to Present at Jefferies Global Healthcare Conference

ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET. Management will also be av

GlobeNewswire 11 days ago

KALA
-1.79%
Wall Street Analysts Just Trimmed Price Target for KALA BIO, Inc. (NASDAQ:KALA)

European stocks started the day on May 21 with a slightly weaker note, marking a retreat from their recent impressive performance, with attention now shifting towards the upcoming earnings report from NVIDIA. The Stoxx 600 index dipped by 0.2%, showing a predominantly negative trend across most sectors, while futures for US equities remained relatively unchanged. […]

Insider Monkey 18 days ago

KALA
-1.79%
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal diseases, including LSCD and to explore KPI-014 in rare inherited retinal diseases -- -- Cash resources of $48.5 million as of March 31, 2024 together with anticipated funding remaining from CIRM award expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- KALA BIO

GlobeNewswire 25 days ago

KALA
-1.79%
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash resources as of December 31, 2023, together with proceeds from the March 2024 private placement and anticipated funding remaining from CIRM award, expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceuti

GlobeNewswire 2 months ago

KALA
-1.79%
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, will present a corporate overview at the TD Cowen 44th Annual Healthcare Conference being held in Boston on Monday, March 4, 2024 at 12:50 p.m. ET. Management will also

GlobeNewswire 3 months ago

KALA
-1.79%
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, which is being held virtually. A pre-recorded fireside chat will be made available beginning on Tuesday, February 13, 2024 at 12:00 p.m.

GlobeNewswire 3 months ago

KALA
-1.79%
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 3,125 shares of its common stock to one new employee. The stock options were granted on January 16, 2024. The grant was

GlobeNewswire 4 months ago

KALA
-1.79%
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 ---- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with anticipated remaining funding from CIRM award, expected to fund operations into 2Q 2025 -- ARLINGTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe

GlobeNewswire 6 months ago

KALA
-1.79%
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in New York, NY. A pre-recorded presentation will be made available beginning on Monday, September 11, 2023 at 7:

GlobeNewswire 8 months ago

KALA
-1.79%
Sidoti Events, LLC’s Virtual August Micro-Cap Conference

Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 16-17, 2023. The presentation schedule is subject to change.

ACCESSWIRE 9 months ago

PCSA

SIDU

TKNO
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

-- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024 -- -- Combangio, Inc., a wholly owned subsidiary of KALA, awarded $15 million grant by California Institute for Regenerative Medicine (CIRM) to support ongoing KPI-012 program for the treatment of PCED ---- Rebranded to KALA BIO, Inc. reflecting focus on advancing biologics for the treatment of rare, serious ophthalmic diseases ---- As of June 30, 2023, $59.2 mi

GlobeNewswire 10 months ago

KALA
-1.79%
KALA BIO to Participate in Upcoming Investor Conferences in August

ARLINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will participate in the following investor conferences in August 2023: 2023 Wedbush PacGrow Healthcare ConferenceDate: Wednesday, August 9, 2023Company management will be available for 1x1 investor meetings in New Yor

GlobeNewswire 10 months ago

KALA
-1.79%
Kala Pharmaceuticals Announces Name Change to KALA BIO

ARLINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will change its name to KALA BIO, Inc. effective August 2, 2023, to better reflect the company’s focus on advancing biologics for the treatment of ophthalmic conditions. KALA BIO is progressing an innovative pipel

GlobeNewswire 10 months ago

KALA
-1.79%
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARLINGTON, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 450 shares of its common stock to one new employee. The stock options were granted on July 14, 2023. The gr

GlobeNewswire 10 months ago

KALA
-1.79%

Performance Overview

Return	KALA	S&P 500
YTD	-6.14%	+12.10%
1-Year	-58.52%	+24.82%
3-Year	-97.76%	+26.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

KALA BIO, Inc. (KALA)

KALA BIO to Present at Jefferies Global Healthcare Conference

Wall Street Analysts Just Trimmed Price Target for KALA BIO, Inc. (NASDAQ:KALA)

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sidoti Events, LLC’s Virtual August Micro-Cap Conference

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO to Participate in Upcoming Investor Conferences in August

Kala Pharmaceuticals Announces Name Change to KALA BIO

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Performance Overview